Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210638 | 0.91 | CYP2A6 (0.83) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2092747 | 0.83 | CYP2A6 (0.71) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL6422681 | 0.80 | CYP2A6 (0.67) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL29017448 | 0.78 | CYP2A6 (0.64) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL423281 | 0.78 | CYP2A6 (0.64) | CYP2A6CA2MAPTLMNATP53 | |
| SCHEMBL8742353 | 0.78 | CYP2A6 (0.60) | CYP2A6KEAP1NFE2L2MAPTLMNA | |
| SCHEMBL7917778 | 0.77 | CYP2A6 (0.62) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL3682441 | 0.77 | CYP2A6 (0.62) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL15191852 | 0.76 | CYP2A6 (0.61) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL788066 | 0.75 | CYP2A6 (0.60) | CYP2A6CA2MAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326790-A1 | PEPTIDES BINDING TO HYPOXIA INDUCIBLE FACTORS AND THEIR USE | UNIVERSITY OF SOUTHAMPTON (GB) | 2025-10-23 | — | — | US | claimed |
| EP-4298110-A1 | PEPTIDES BINDING TO HYPOXIA INDUCIBLE FACTORS AND THEIR USE | UNIVERSITY OF SOUTHAMPTON (GB) | 2024-01-03 | — | — | EP | claimed |
| WO-2022180410-A1 | PEPTIDES BINDING TO HYPOXIA INDUCIBLE FACTORS AND THEIR USE | UNIVERSITY OF SOUTHAMPTON (GB) | 2022-09-01 | — | — | WO | claimed |
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | claimed |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2017-07-06 | — | — | US | claimed |
| EP-2944633-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2015-11-18 | — | — | EP | claimed |
| EP-0853618-B1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2011-08-17 | — | — | EP | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| US-20250326790-A1 | PEPTIDES BINDING TO HYPOXIA INDUCIBLE FACTORS AND THEIR USE | UNIVERSITY OF SOUTHAMPTON (GB) | 2025-10-23 | — | — | US | disclosed |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4298110-A1 | PEPTIDES BINDING TO HYPOXIA INDUCIBLE FACTORS AND THEIR USE | UNIVERSITY OF SOUTHAMPTON (GB) | 2024-01-03 | — | — | EP | disclosed |
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| WO-2022180410-A1 | PEPTIDES BINDING TO HYPOXIA INDUCIBLE FACTORS AND THEIR USE | UNIVERSITY OF SOUTHAMPTON (GB) | 2022-09-01 | — | — | WO | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
| EP-0344979-A2 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0117675-B1 | BENZOFURAN AND BENZOTHIOPHENE-CARBOXYLIC-ACID DERIVATIVES | BEECHAM GROUP PLC (GB) | 1986-07-23 | — | — | EP | disclosed |
| US-4548948-A | Anti-inflammatory and analgesic benzothiophene and benzafuran derivatives, compositions, and method of use therefor | BEECHAM GROUP P.L.C. (GB) | 1985-10-22 | — | — | US | disclosed |
| US-4492693-A | BACTERICIDES, ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-01-08 | — | — | US | disclosed |
| EP-0122154-A2 | Improvements in or relating to benzothienylglycyl cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
| EP-0117675-A1 | Benzofuran and benzothiophene-carboxylic-acid derivatives | BEECHAM GROUP PLC (GB) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, AR, SHBG | CYP2A6 992/4885KEAP1 2359/4885NFE2L2 1811/4885 |
| US-20250326790-A1 | PEPTIDES BINDING TO HYPOXIA INDUCIBLE FACTORS AND THEIR USE | HIF1A, HIF1AN, HYOU1 | CYP2A6 4527/4885KEAP1 462/4885NFE2L2 57/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | CYP2A6 3830/4885KEAP1 4633/4885NFE2L2 4610/4885 |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | HPRT1, XDH, NUDT1 | CYP2A6 1634/4885KEAP1 1111/4885NFE2L2 2380/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | CYP2A6 2283/4885KEAP1 1/4885NFE2L2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.